AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
2014 · Cancer Discovery · 2,163 citations
https://doi.org/10.1158/2159-8290.cd-14-0337
C
Caroline A. Nebhan
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
105
Papers
4.9K
Citations
19
h-index
24
i10-index
Caroline A. Nebhan is an academic researcher from Vanderbilt University. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Cancer Immunotherapy and Biomarkers & HER2/EGFR in Cancer Research. The author has an h-index of 19, co-authored 90 publications.
ORCID: 0000-0002-9402-7284Papers by this author
worksImmune-checkpoint inhibitors: long-term implications of toxicity
2022 · Nature Reviews Clinical Oncology · 869 citations
https://doi.org/10.1038/s41571-022-00600-w
N-WASP and the Arp2/3 Complex Are Critical Regulators of Actin in the Development of Dendritic Spines and Synapses
2008 · Journal of Biological Chemistry · 232 citations
https://doi.org/10.1074/jbc.m801555200
Vasodilator-stimulated Phosphoprotein (VASP) Induces Actin Assembly in Dendritic Spines to Promote Their Development and Potentiate Synaptic Strength
2010 · Journal of Biological Chemistry · 44 citations
https://doi.org/10.1074/jbc.m110.129841
Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and Survival
2023 · Cancers · 9 citations
https://doi.org/10.3390/cancers15205052
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat